Creating a compliant and scalable CGT logistics launch plan
As cell and gene therapies (CGTs) move from clinical trials to commercial launches, biopharmaceutical companies need to address complex logistical challenges with a strategy that’s customized to their product. Assessing their product’s requirements — such as for temperature controls and regulatory compliance — will ensure a smoother end-to-end delivery and help avoid supply chain disruptions.
The logistics decisions that you need to make when commercializing your cell or gene therapy are complex. Read six expert tips for handling them — from cryogenic shipping to biohazard disposal.
Fill out the form below to read article
Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.
Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.